In the rapidly evolving field of neuroscience, the quest to unlock the complexities of cognitive diseases has taken a significant turn with recent studies investigating the therapeutic potential of nicotinamide adenine dinucleotide (NAD+) precursors. A systematic review led by researchers Qader, M.A., Hosseini, L., and Abolhasanpour, N. highlights the impact of NAD+ precursors on cognitive diseases in preclinical rodent models. The research sheds light on the role of NAD+, a crucial coenzyme found in every living cell, in promoting neuronal health and function.
The systematic review meticulously aggregates findings from various studies to examine how the enhancement of NAD+ levels can influence cognitive performance in rodents. This line of research is particularly important in light of the increasing prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where cognitive decline poses profound challenges not only to individuals but also to healthcare systems worldwide. The review underscores the importance of NAD+ not just as a metabolic cofactor but as a potential game-changer in the treatment of cognitive disorders.
One of the distinctive features of this review is its comprehensive approach in examining both the sources of NAD+ and the pathways through which it can exert beneficial effects on brain health. The authors discuss various precursors of NAD+, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both of which have shown promise in preclinical settings to elevate NAD+ levels effectively. By increasing NAD+, these compounds may help restore energy metabolism in neurons, thus potentially thwarting the progression of cognitive decline.
Interestingly, the review also delves into the underlying mechanisms by which NAD+ influences neuroprotection. The authors detail how NAD+ plays a pivotal role in cellular energy production and repair processes, instigating cellular signaling pathways that are crucial for maintaining neuronal integrity. The potential of NAD+ to activate sirtuins, a family of proteins known to regulate cellular stress responses, further highlights its importance in protecting against oxidative stress—one of the major contributors to neuronal damage in cognitive disorders.
Moreover, the systematic review discusses the implications of NAD+ in modulating neuroinflammation, a common hallmark in many cognitive diseases. Increased levels of NAD+ are linked with reduced activation of inflammatory pathways, which can contribute to a healthier neural environment. The authors synthesize data showing that supplementation with NAD+ precursors could result in decreased microglial activation and downregulation of pro-inflammatory cytokines, pointing toward a promising avenue for therapeutic intervention in neurodegenerative conditions.
The review does not shy away from addressing the need for further research, particularly in the translation of these findings from rodent models to human applications. While preclinical studies have shown encouraging results, the complexities of human biology require thorough clinical trials to establish safety and efficacy. The authors emphasize that understanding the pharmacokinetics and optimal dosing strategies of NAD+ precursors will be vital in paving the way for future therapeutic options in cognitive health.
A notable point in the review is its acknowledgment of the role of lifestyle factors in modulating NAD+ levels. The authors suggest that diet, exercise, and even sleep could influence NAD+ metabolism, potentially offering a multifaceted approach to cognitive health. For instance, certain dietary interventions, such as increased intake of niacin-rich foods, could be a natural method to enhance NAD+ levels and improve brain health.
Moreover, the review highlights the synergistic effects of combining NAD+ precursors with other therapeutic agents, such as antioxidants and amyloid-beta-targeting therapies. The potential for a multifactorial approach could lead to more effective treatment strategies for cognitive decline, underscoring the importance of future studies exploring these combinations.
Another area of interest within the review is the differences in response to NAD+ precursors based on age and genetic predisposition. It is posited that younger rodent models may exhibit a more significant improvement in cognitive performance when supplemented with NAD+ precursors compared to older models. This raises essential questions about the timing of interventions and the need for personalized approaches in cognitive disease treatments based on individual genetic and biological profiles.
In conclusion, the systematic review by Qader, M.A., Hosseini, L., and Abolhasanpour, N. serves as a clarion call for enhanced focus on NAD+ metabolism in cognitive disease research. With increasing evidence supporting its protective roles, NAD+ precursor supplementation could represent a significant advancement in the way we approach cognitive health and disease prevention. As we stand on the brink of potentially groundbreaking interventions for cognitive diseases, the findings of this review provide a critical foundation for future research and clinical applications in the realm of neuroscience.
As the field continues to explore the intricacies of NAD+ and its role in brain health, the urgency for innovative solutions to combat cognitive decline grows ever more palpable. The pathway to understanding how NAD+ can be harnessed for therapeutic purposes is filled with exciting possibilities, and the scientific community is poised to embark on this journey of discovery.
Subject of Research: Therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases
Article Title: A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models
Article References:
Qader, M.A., Hosseini, L., Abolhasanpour, N. et al. A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models.
BMC Neurosci 26, 17 (2025). https://doi.org/10.1186/s12868-025-00937-9
Image Credits: AI Generated
DOI: 10.1186/s12868-025-00937-9
Keywords: NAD+, cognitive diseases, nicotinamide adenine dinucleotide precursors, neuroprotection, preclinical research
